The cAMP-protein kinase A (PKA) pathway is the major signal transduction pathway involved in melanocytestimulating hormone receptor-mediated signaling and melanin production, whereas its role in the control of melanocyte proliferation is still controversial. In this study, we evaluated the effects of selective activation of the different PKA regulatory subunits type 1A (R1A) and type 2B (R2B) on melanocyte proliferation. Immunohistochemistry demonstrated that normal melanocytes lacked R1A protein whereas this subunit was highly expressed in all human melanomas studied (N ¼ 20) and in six human melanoma cell lines. Pharmacological activation of the R2 subunits by the cAMP analogue 8-Cl-cAMP inhibited proliferation and increased caspase-3 activity by 68.77 ± 10.5 and 72 ± 9% respectively, in all cell lines with the exception of the only p53-mutated one. Similar effects were obtained by activating R2 subunits with other analogues and by silencing R1A expression. The antiproliferative and proapoptotic effects of 8-Cl-cAMP were comparable to those observed with commonly used antitumoral drugs. Moreover, 8-Cl-cAMP potentiated the effects of these drugs on both cell proliferation and caspase-3 activity. In conclusion, this study first reports that human melanomas are characterized by a high R1/R2 ratio and that pharmacological and genetic manipulations able to revert this unbalanced expression cause significant antiproliferative and proapoptotic effects in melanoma cells.
Introduction
Cyclic AMP is implicated in the regulation of a variety of cell functions that are, at least in part, related to protein phosphorylation through the activation of protein kinase A (PKA). In addition to the control of differentiated functions, cAMP inhibits or stimulates cell proliferation depending on the cell type. Recently, mutations of genes involved in cAMP signaling and resulting in the constitutive activation of cAMP formation have been identified as cause of endocrine neoplasia (Landis et al., 1989; Weinstein et al., 1991; Kirschner et al., 2000; Lania et al., 2001) . In particular, germ-line mutations of the gene encoding the PKA type 1A regulatory subunit (R1A) have been demonstrated to be involved in the pathogenesis of Carney complex (Kirschner et al., 2000) , while activating mutations of the Gs-a gene lead to the McCune-Albright syndrome (Weinstein et al., 1991) .
Dramatic changes in the proportion of the two PKA regulatory subunits, R1 and R2, occur during ontogenic development, differentiation processes and neoplastic transformation, indicating distinct roles for these isoenzymes in growth control (Cho-Chung, 1990; Tortora et al., 1990) . In particular, several studies support the view that R1 is related to cell proliferation whereas R2 is primarily involved in tissue differentiation (Tortora et al., 1990; Cho-Chung et al., 1995) . Accordingly, in a variety of human cancer cell lines, transformation coincides with a sharp increase in R1, while R2 overexpression reverts the malignant into a non-transformed phenotype (Handschin and Eppenberger, 1979; Rohlff et al., 1993; Nesterova et al., 1996; Cho et al., 2000; Cho-Chung and Nesterova, 2005) . Changes in PKA regulatory subunit expression in tumors are not exclusively due to mutational events, as demonstrated in tumoral pituitary cells that are characterized by low or absent expression of the R1A subunit protein due to proteasome-dependent protein degradation, this unbalanced expression resulting in cell proliferation (Lania et al., 2004) .
Interestingly, the two human diseases known to be determined by mutations in the cAMP-dependent pathway, that is Carney complex and McCune-Albright syndrome, include heterogeneous pigmented lesions of skin and mucosa. The cAMP-PKA pathway is the major signal transduction pathway involved in melanocyte-stimulating hormone receptor-mediated signaling, melanin production and melanocyte differentiation (Levine et al., 1991; Hunt et al., 1994) , although its role in controlling melanocyte proliferation is still controversial. Indeed, a-melanocyte-stimulating hormone (MSH) was shown to stimulate melanocyte proliferation in vitro (De Luca et al., 1993) , even if many data indicate an antiproliferative role of cAMP in these cells (Dumaz and Marais, 2005) .
This study demonstrates that melanomas are characterized by a high R1/R2 ratio and that pharmacological and genetic manipulations able to revert this unbalanced expression cause significant antiproliferative and proapoptotic effects in melanoma cells.
Results

Immunohistochemistry
Consecutive slices of 10 normal skin controls showed a strong immunopositivity for R2A and R2B subunits of PKA in normal melanocytes, while no immunoreactivity for R1A was detected (Figure 1a) . Conversely, all melanoma lesions showed a strong immunoreactivity for all three regulatory subunits ( Figure 1a) . No correlation was observed between R subunit expression and Clark's level, SSM or NM nature and presence or absence of BRAF and NRAS mutations.
As for cell lines, 232702, 2101568, 21768, 26258, 501 and 1402 cells showed a pattern of PKA regulatory subunit expression similar to that observed in human tumors, with a strong expression of R1A, R2A and R2B proteins as demonstrated both by immunocytochemistry and western blotting (Figure 1b) . Furthermore, two human normal melanocyte cell lines used as control still expressed PKA R2A and R2B, but almost totally lacked the R1A subunit (Figure 1b) , similar to normal skin data.
In accordance with the notion that PKA R1B is typically associated to the central nervous system, no R1B transcript was detected by reverse transcriptase-PCR analysis neither in melanoma or in normal melanocyte cell lines (data not shown).
Effect of cAMP analogues on cell proliferation
We investigated the role of the different PKA regulatory subunits on cell proliferation in six melanoma cell lines.
Figure 1 (a) Immunostaining for the three protein kinase A regulatory subunits (R1A, R2A and R2B) performed in a human melanoma, as representative example (upper panels). Similar data were obtained in other 19 primary tumors. The lower panels show consecutive slices of a normal skin section in which both R2A and R2B subunits are present in melanocytes (arrows), while no immunostaining for R1A was observed in consecutive sections of the same sample. Similar results were obtained in nine additional skin sections from nine different subjects. All photomicrographs are shown at an original magnification of Â 25. (b) Western blot analysis with the same antibodies in the six human melanoma cell lines and in two normal melanocyte cell lines: melanoma cells abundantly express the three regulatory subunits, while normal melanocytes almost totally lack the R1A subunit.
In all lines, with the exception of 1402, the two cAMP analogues able to selectively activate R2 subunit (Cho-Chung, 1990; Schwede et al., 2000) , that is 8-Cl-cAMP and 6-MBC-cAMP, caused a significant and dose-dependent inhibition of cell proliferation (Figures 2a and b) . In particular, despite cell line-related differences, 8-Cl-cAMP caused a significant and dosedependent inhibition of cell proliferation at concentrations higher than 0.5 and 5 mM in line 21768 and in the other four lines, respectively, with a reduction vs basal levels of 68.77±10.5% at 100 mM in the five cell lines (Figure 2a ). This event was accompanied by a significant induction in R2B protein and a reduction in R1A (Figure 2a) . The R2-mediated inhibition of cell proliferation was confirmed by the incubation with 6-MBCcAMP, which caused a significant inhibition in all cell lines (26±2.8% at 100 mM) with the exclusion of 1402. Conversely, the selective activation of R1A subunit by 8-HA-cAMP (Schwede et al., 2000) induced a significant increase in cell proliferation ( þ 43.1 ± 22% over basal levels at 10 mM) (Figure 2b ). Co-incubation with the PKA inhibitor PKI (5 mM) resulted in a significant reduction of the effects on cell proliferation induced by 8-Cl-cAMP, 6-MBC-cAMP and 8-HA-cAMP ( Figure 2b ). Conversely, none of these pharmacological manipulations were able to influence the proliferation of 1402 cells.
We then asked whether the antiproliferative effect of R2-selective analogues was comparable to that obtained with commonly used antineoplastic drugs. To this purpose, we focused on the cell line 21768, as the best responsive to cAMP analogues in terms of cell proliferation inhibition. The antiproliferative effect obtained with high concentrations of vinblastine and cisplatin (100 and 10 mM, respectively) after 72 h incubation was similar to that induced by 10 mM 8-Cl-cAMP (Figure 2c ). In these experimental conditions, addition of 8-ClcAMP to vinblastine and cisplatin did not modify the effects induced by each agent alone (Figure 2c ). Conversely, co-incubation of 8-Cl-cAMP at 0.1 mM, a concentration ineffective on cell proliferation (Figure 2a) , with low doses of vinblastine (1 mM) or cisplatin (1 mM) resulted in a significant increase of the antiproliferative action caused by the antiblastic drugs alone (Figure 2c ).
Effect of cAMP analogues on apoptosis
In all lines, with the exception of 1402, the exposure to progressively higher concentrations of 8-Cl-cAMP and, to a less extent, 6-MBC-cAMP, induced a progressive increase in caspase-3 activity, with a maximum increase of 72 ± 9 and 32 ± 7% vs basal, respectively, at 100 mM (Figures 3a and b) . Similar results were obtained by fluorescence activated cell sorting (FACS) staining with Annexin V-fluorescein isothiocyanate (data not shown). As for the antiproliferative effect, the induction of apoptosis was at least in part mediated by PKA activation, as demonstrated by the partial inhibition obtained by co-incubation with PKI (mean inhibition in the five cell lines: 25.3±4 and 20.3±3.6% vs 8-Cl-cAMP-and 6-MBC-cAMP-stimulated caspase-3 activity, respectively) ( Figure 3b ).
The classic antineoplastic agents cisplatin and vinblastine induced the expected proapoptotic effect in the cell line 21768. Moreover, as shown for the antiproliferative effect, the proapoptotic effect of cisplatin 1 mM and vinblastine 1 mM was potentiated by co-incubating these drugs with 8-Cl-cAMP at concentrations unable to affect caspase-3 activity when used alone (2 mM) ( Figure 3c ).
Since the only cell line that did not respond to 8-ClcAMP was 1402, the only line carrying, in addition to the BRAF mutation, a Y236H mutation of p53, we investigated the effect of 8-Cl-cAMP on p53 expression in these cells and in a cell line carrying wild-type p53 (21768 as a representative example). In basal conditions, 21768 cells weakly expressed p53 protein, while p53 appeared to be overexpressed in 1402 cells. A 6 h incubation with 100 mM 8-Cl-cAMP induced a two-fold increase in p53 levels in 21768 cells, while no change was observed in 1402 cells (Figure 4 ).
R1A gene silencing
The effect of changes in R1A/R2B ratio on cell proliferation was further investigated in 232702, 21768 and 501 cells by silencing R1A RNA expression by small interfering RNA (siRNA) transfection. The near-total abrogation of R1A protein levels obtained by this manipulation was associated with significant inhibition of proliferation (27.4 ± 9%) and induction of apoptosis In the five responsive cell lines, also the more specific R2-selective cAMP analogue 6-MBC-cAMP was able to inhibit cell proliferation at high concentrations (100 mM). Conversely, 8-HA-cAMP (10 mM), a selective R1 activator, caused a significant increase of cell proliferation. These effects were partially abolished by protein kinase A blockade with PKA inhibitor (PKI). Data are expressed as percentage vs non-stimulated cells and represent the mean±s.d. of determinations carried out in quintuple in at least three independent experiments, in five responsive cell lines. (c) Comparison between the antiproliferative effect of R2-selective analogues and cisplatin and vinblastine in the cell line 21768. The maximum effect obtained with 10 mM 8-Cl-cAMP was similar to that obtained after 72 h incubation with high concentrations of vinblastine (100 nM) and cisplatin (10 mM). The antiproliferative action of low doses of antiblastic drugs was significantly potentiated by co-incubation with 0.1 mM 8-Cl-cAMP, while no further effect was obtained by co-incubating the cell with these agents at high concentrations. Data are expressed as relative fluorescence units (RFU), and represent the mean ± s.d. of determinations carried out in quintuple in at least three independent experiments. *Po0.01 vs basal; PKA regulatory subunits in human melanoma cells G Mantovani et al (18±1.6%), an effect similar to that obtained by concentrations of 8-Cl-cAMP between 2 and 10 mM depending on the cell line examined (Figure 5a ). These effects were accompanied by a marked increase in R2B levels, as assessed by western blot analysis, suggesting that the observed antiproliferative effect was indeed determined by R1A abolishment and R2B induction (Figure 5a ).
To further support our hypothesis that a high R1/R2 ratio promotes cell proliferation in human melanoma cells, we separately silenced R2A and R2B in our cell system: both manipulations lead to a modest yet significant increase in cell proliferation after 72 h (17.4 ± 5.2 and 15.2 ± 4.9%, respectively), with no evident effect on R1A expression, as might be expected by the fact that these cells still express one of the two R2 subunits (Figure 5b) . 
Discussion
This study first reported that human melanomas were characterized by an altered ratio in the expression of the two PKA regulatory subunits R1 and R2 and that pharmacological and genetic manipulations able to revert this unbalanced expression caused significant antiproliferative and proapoptotic effects in melanoma cells. Human melanocytes require various signaling pathways to maintain the fine balance between proliferation and differentiation. It is well known that the cAMP-PKA pathway is the major signal transduction pathway involved in melanocyte-stimulating hormone receptormediated signaling and melanin production, whereas the role of this pathway in the control of melanocyte proliferation is still controversial (Dumaz and Marais, 2005) . However, clinical evidence suggests that mutational changes in different components of the cAMP pathway resulting in constitutive activation of cAMP/ PKA signaling are associated with melanocyte proliferation. In particular, both Carney complex and McCune-Albright syndrome include heterogeneous pigmented lesions of skin and mucosa. This has led us to investigate the pattern of expression of the different subtypes of PKA regulatory subunits in human melanomas compared with normal melanocytes and to identify their potential role in the control of cell proliferation.
Immunohistochemistry demonstrated a strong immunoreactivity for the R1A protein in all human melanomas included in our study, as well as in the six human melanoma cell lines investigated. In contrast, normal melanocytes completely lacked R1A subunit, still expressing R2A and R2B. These data indicated a high R1/R2 ratio in melanomas if compared with the normal counterpart, according to previous data from a variety of human cancer cell lines in which transformation coincides with a sharp increase in R1A.
The effects of the abnormally high R1/R2 ratio found in melanomas on proliferation was assessed in human melanoma cell lines and the data obtained showed an important impact of R1/R2 ratio on cell growth. First, the R2-selective cAMP analogues 8-ClcAMP and 6-MBC-cAMP dose-dependently and significantly inhibited cell proliferation (Figure 2 ). This event was also accompanied by a significant induction in R2B protein and a reduction in R1A. Consistently, R1A selective agonists caused a significant stimulation of melanoma cell proliferation, further supporting the involvement of R1A downregulation in the inhibitory signal elicited by 8-Cl-cAMP. Second, 8-Cl-cAMP and 6-MBC-cAMP were effective in inducing apoptosis Figure 4 Effect of 8-Cl-cAMP on p53 expression on p53-mutated cell line (1402) and in a p53 wild-type cell line (21768 as a representative example). These cell lines also differ in responsiveness to cAMP analogues in terms of cell proliferation and apoptosis (upper panels). As shown in lower panels, in basal conditions, 21768 cells weakly expressed p53 protein, while p53 was overexpressed in 1402 cells. Incubation with 100 mM 8-Cl-cAMP for 6 h induced a marked increase of p53 levels in 21768 cells, with no change in 1402 cells. The figure shows western blot performed loading 20 mg of proteins; to exclude that p53 overexpression in line 1402 might mask a further induction by 8-Cl-cAMP, the same experiment was performed using 10 and 5 mg of proteins, with similar results. Western blot data represent an example of at least three independent experiments. *Po0.01 vs basal. (Figure 3 ), as indicated both by the increased enzymatic activity of caspase-3, a major protease mediator of the extrinsic and intrinsic apoptotic pathways, and by Annexin V FACS analysis. Both the antiproliferative and the proapoptotic effects of 8-Cl-cAMP were partially abrogated by specific PKA inhibitors, suggesting the involvement of PKA-dependent and independent pathways in this effect. The interactions of the regulatory and catalytic PKA subunits with other signaling pathways, such as the extracellular signal-regulated Figure 5 (a) Effect of R1A RNA silencing experiments on R2B protein levels (upper panels) and on cell proliferation and apoptosis (lower panels) in 21768 cells, as representative example. Western blot analysis with the specific R1A and R2B antibodies and evaluation of cell proliferation and apoptosis were carried out after 72 h exposure to small interfering RNA (siRNA) for human R1A gene. The near-total abrogation of R1A protein levels obtained by this manipulation was associated with a marked increase in R2B levels, a significant inhibition of cell proliferation and induction of apoptosis. These effects were similar to those obtained by concentrations of 8-Cl-cAMP between 2 and 10 mM depending on the cell line examined. (b) Effect of R2A and R2B RNA-silencing experiments on R2A, R2B and R1A protein levels (upper panels) and cell proliferation (lower panel) in 21768 cells, as representative example. All data represent the mean ± s.d. of determinations carried out in triplicate in at least three independent experiments. CÀ ¼ negative control represented by cells transfected with the corresponding scrambled siRNA. *Po0.01 vs basal. kinase kinase 1/2 cascade, have been documented in several cell lines, including melanoma cells (Dumaz and Marais, 2005) . Indeed, in primary and metastatic human melanomas and melanoma cell lines, the extracellular signal-regulated kinase pathway is frequently activated by mutations in BRAF or, less frequently, NRAS genes (Davies et al., 2002; Curtin et al., 2005; Miller and Mihm, 2006) . Finally, the impact of the high R1/R2 ratio on cell proliferation was further confirmed by siRNA experiments: in fact, the silencing of R1A protein, a manipulation that mimicked the expression pattern found in normal melanocytes, resulted in decreased cell growth, together with induction of apoptosis and upregulation of the R2B protein. On the contrary, silencing of R2A and R2B lead to a modest yet significant increase in cell proliferation ( Figure 5) .
We then asked what was the impact of PKA manipulation on proliferation with respect to that obtained with commonly used antitumoral drugs, such as cisplatin and vinblastine. The maximal antiproliferative and proapoptotic effects observed by pharmacological activation of the R2 subunits and R1A silencing were similar to those observed with these drugs (Figures  2c and 3c) . Moreover, 8-Cl-cAMP at low concentrations significantly amplified the effects induced by these agents, suggesting the activation of at least partially distinct intracellular pathways. However, in analogy with the cisplatin-induced transcription of proapoptotic genes (Siddik, 2003) , evidence suggested that antiproliferative effect of cAMP analogues was associated with the induction of p53. First, of the six human melanoma cell lines evaluated, five showed similar responses to cAMP analogues in term of both proliferation and apoptosis, independently on the presence or absence of BRAF and NRAS mutations (Figure 2) . Conversely, the only cell line in which cAMP analogues completely failed to elicit antiproliferative and/or proapoptotic response, that is line 1402, was characterized by the presence of a mutation in p53 gene (Figures 2 and 3) . Second, in 1402 cells, no change in p53 levels was detected after treatment with the R2-selective cAMP analogue 8-Cl-cAMP, while the same manipulation resulted in a two-fold increase in p53 levels in 232702 cell line (Figure 4) .
In conclusion, our study shows that the appearance of PKA R1A protein, with consequent switch to a high R1/ R2 ratio, is a common event in human melanomas, and that both pharmacological and genetic manipulations able to revert this unbalanced ratio lead to decreased proliferation in human melanoma cells. Importantly, our data also indicate that in melanoma cells, the antiproliferative effect of PKA R2-selective analogues potentiates the growth-inhibitory effect of antitumoral drugs, this being potentially significant in a disease in which treatment options are still poor and often unsuccessful. Further investigation and understanding of the signaling pathways involved in neoplastic transformation of melanocytes will provide the basis for identifying new drugs which could potentiate the effects of cytotoxic compounds or overcome resistance to chemotherapy.
Materials and methods
Melanoma tissues and cell cultures
The study included 20 cutaneous melanoma samples surgically removed from patients aged 40-75 years, 11 women and 6 men. All were primary tumors, 14 were superficial spreading melanomas and six were nodular melanomas. Of them, 13 had Clark's level IV, 2 had level II and 5 had level V. Small sample fragments were fixed for immunohistochemistry and the remaining tissues were quickly frozen for subsequent molecular analysis.
Six melanoma cell lines (232702, 2101568, 1402 obtained from three primary cutaneous tumors and 21768, 26258, 5013 from three cutaneous metastasis, all from sporadic patients) were maintained in RPMI medium supplemented with 10% fetal calf serum, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, glutamine and antibiotics (Biowhittaker, Walkersville, MD, USA) for short-term cultures, not exceeding 10-15 passages. Moreover, two human normal melanocyte cell lines were included as control. Information relative to cell lines are extensively described elsewhere (Daniotti et al., 2004; Tanami et al., 2004) .
All tissue samples and melanoma cell lines were characterized for BRAF, NRAS and p53 mutations (Daniotti et al., 2004) . Of the six cell lines, four were positive for the V600E BRAF mutation (232702, 2101568, 501 and 1402) , while no alterations were detected in the NRAS gene. Line 1402 carried, in addition to the BRAF mutation, a Y236H mutation of p53. Of the 20 tissue samples, 11 were heterozygous for a BRAF mutation and three had mutations of NRAS. No p53 mutations were detected in this series. Local Ethics Committee approval was obtained for all studies.
Immunohistochemistry
Sections from paraffin-embedded tissues from 20 surgically removed melanoma tumors were processed for immunohistochemistry, as reported previously (Lania et al., 2004) . Ten sections from normal skin were included as control. Moreover, the six melanoma cell lines underwent immunocytochemical analysis. Specific monoclonal antibodies for PKA R1A, PKA R2A and PKA R2B were used under the conditions specified by the manufacturer (BD Transduction Laboratories, Lexington, UK). Antigen-antibody detection was performed using the DAKO ChemMate En Vision detection kit (DAKO A/S, Glostrup, Denmark) according to the manufacturer's instructions. Sections were stained with 3,3 0 -diaminobenzidine substrate, counterstained with Meyer hematoxylin and slides prepared for light microscopy examination, as reported previously (Lania et al., 2004) . Negative controls were obtained by occulting the primary antibody or by using an unrelated mouse monoclonal antibody.
Western blot
Western blotting was performed as described previously (Lania et al., 2004) . PKA R1A (49 kDa), PKA R2B (53 kDa) and p53 protein (53 kDa) were detected using specific monoclonal antibodies (BD Transduction Laboratories, Lexington, KY for PKA R1A and R2B; DAKO A/S, Glostrup, Denmark for p53).
Cell proliferation
Cell proliferation was assessed by colorimetric measurement of 5-bromo-2 0 -deoxyuridine incorporation during DNA synthesis in proliferating cells (Cell Proliferation Biotrak Elisa, Amersham, Piscataway, NJ, USA). Briefly, cells were cultured in 96-well plate (10 000 cells per well) in the presence of test substances 8-Cl-cAMP (0.1-100 mM),6-MBC-cAMP (5-100 mM) þ 100 mM Sp-5,6-DCl-cBIMPS and 8-HA-cAMP (5-100 mM) þ 90 mM 8-PIP-cAMP from Biolog, Germany; Vinblastine (1-100 mM), Cisplatin (1-10 mM), from (SigmaAldrich, Milan, Italy). 8-PIP-cAMP and Sp-5,6-DCl-cBIMPS are site-selective cyclic AMP analogues with high selectivity for site A of PKA type 1 and for site B of type 2, respectively. They act synergistically with other analogues having opposite site selectivity. In particular, combination of 8-PIP-cAMP with 8-HA-cAMP preferentially activates PKA type 1, while combination of Sp-5,6-DCl-cBIMPS with 6-MBC-cAMP selects type 2 (Schwede et al., 2000) . All these agents were used alone or in combination with the cell permeant PKA inhibitor PKI, 5 mM (Sigma-Aldrich) for 72 h at 37 1C and then with 5-bromo-2 0 -deoxyuridine for 2 h to allow 5-bromo-2 0 -deoxyuridine incorporation in newly synthesized cellular DNA. Proliferation was expressed as relative fluorescence units. All experiments were repeated at least three times on six different melanoma cell lines, and each determination was done in quintuple.
Evaluation of apoptosis
Apoptosis was evaluated both by measurement of caspase-3 activity and by FACS staining with Annexin V-fluorescein isothiocyanate. Caspase-3 enzymatic activity was measured using Apo-ONE Homogenous Caspase-3 Assay (Promega Corp., Madison, WI, USA), a fluorescent assay based on cleavage of the non-fluorescent caspase substrate Z-DEVD-R110 by caspase-3 to create the fluorescent Rhodamine 110. Cells were seeded in 96-well plates (50 000 cells per well) and treated with or without the same agents used for proliferation assays for 72 h at 37 1C, in RPMI supplemented with 10% fetal calf serum. Fluorescence was measured at an excitation at 485±20 nm and an emission at 530±25 nm. Caspase-3 activity was indicated by net fluorescence (assay RFLU-blank RFLU). Experiments were repeated at least three times and each determination was done in triplicate.
For FACS analysis, 3.5 Â 10 6 cells seeded in 10 cm petri dishes were treated after 24-h culture with for 16 h. Annexin V-fluorescein isothiocyanate and propidium iodide staining was used to detect early apoptotic cells as indicated by the manufacturer (Becton Dickinson, San Jose, CA, USA), as described previously (Di Stasi et al., 2005) . Cells were then subjected to flow cytometry analysis using a FACScan (Becton Dickinson); 10 000 events were considered.
Synthesis and transfection of siRNA Small interfering RNA for human R1A, R2A and R2B genes were synthesized by Dharmacon (Chicago, IL, USA), and 232702, 21768 and 501 melanoma cell lines were transfected with the double-stranded RNA through JetsiENDO transfection Reagent (Polyplus transfection, New York, NY, USA), according to the manufacturer's instructions and as reported previously (Lania et al., 2004) . Cells were exposed to doublestranded RNA and transfection reagent for 72 h before performing proliferation and apoptosis assays. Western blot analysis was carried out with the specific R1A, R2A and R2B antibodies to control the effective silencing of the genes. Corresponding scrambled siRNA for the same regulatory subunits and siRNA for GAPDH were used as internal negative and positive controls, respectively.
Statistical analysis
The results are expressed as the mean±s.d. A paired or unpaired two-tailed Student's t-test was used to detect the significance between two series of data. Po0.05 was accepted as statistically significant.
